On Dec 2, 12:25 pm, Panchofabricio <panchofabri...@gmail.com> wrote:

On Dec 1, 11:57 pm, Julian Ward <julianrw...@gmail.com> wrote:

On Nov 30, 4:18 pm, Malsibob <tarek.elmess...@gmail.com> wrote:

On Nov 30, 3:57 pm, Steve Silverman <sgoldman...@gmail.com> wrote:

On Nov 28, 3:59 pm, Ichie1 Nibo <ichieni...@gmail.com> wrote:

On Nov 13, 3:58 pm, ttn <nguyentt...@gmail.com> wrote:

Join us at http://groups.google.com/group/market-mafia

******

ECOB  Products; a fully integrated chemical coating plant located in
Southern California and Northeast Texas, poised to impact housing
industry on many levels.

ECOB aims at preventing rot, mildew, fungus, termite infestation,
along with effective fire retardant. Coated wood lasts Lifelong;
increases sustainability of forests.

Estimated Market demand for treated lumber is $11 Billion by 2010.
Demand for lumber and engineering wood products is expected to be $18
Billion.

The management team made up to Founder Steve Conboy and EVP Mark
Vuzzo, having more than 30 years of experience each; and the Advisory
team consisting of Ken McClelland- president of McClelland
Organization. The ECoBlu seems to be in have a great leaders.

ECO Blu is superbly positioned to take advantage in this rapidly
increasing eco friendly and Green market.

ECOB  have an estimated growth of about $6 billion within 3 years.
This would represent a gain of over 200% from current level.

The wood chemical market enjoyed $2 Billion in revenues in 2007, ones
the global financial market recovers the revenues are expected to
exceed the numbers.

Partnership with Lowe’s had enabled EcoBlu to implement new strategies
and boost contractor sales.

EcoBlu have established Nationwide Sales and Marketing of coatings
chemistry in South America, Caribbean, Africa and Asia.

A Three year plan of ECOB calls for direct selling of chemicals
coatings to mills, EWP manufacturers and independent coaters in the US
and elsewhere, than just selling to retailers and other small
builders.

Power3 Medical is a breakthrough proteomics company specializing in
the identification of disease footprints in the areas of
chemotherapeutic drug resistance and the early detection of breast
cancer and neurological diseases opposed to late stage detection.

They have recently filed for 3 utility patents due to their advances
in early stage breast canc
 Proteomics is the study and analysis of proteins, the fundamental
building blocks of the human body. By studying proteins, scientists
can understand more fully the functioning of a healthy body and
identify the proteins associated with specific diseases. Proteins are
not only the building blocks for life; in them, evidence can be found
for serious diseases such as cancer, neurodegenerative disease
     * Breast Cancer
    * Alzheimer’s Disease
    * ALS (Lou Gehrig’s Disease)
    * Parkinson’s Disease
    * Leukemia
    * Gastrointestinal Disease
    * Metabolic Syndrome
    * Chemotherapeutic Drug Resistance

 These discovered and patent-pending biomarkers solve critical
challenges facing pharmaceutical and diagnostic companies and are
currently being used to design tests to diagnose diseases and discover
targets for new drugs to treat the diseases.

Each validated biomarker, pattern, new diagnostic test, or drug
target, may have a potential market value from $10 – $100 million plus

RECENT NEWS:

 PWRM Announced that its Chief Scientific Officer is Chair and Keynote
Speaker of Session at the BTI Life Sciences 2nd Annual Congress and
Expo of Molecular Diagnostics in Beijing, China in November 2009

Further international recognition of validity as the company’s
President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote
address and chair a session on “Biomarkers and Diagnostics in
Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd
International Congress and Expo of Molecular Diagnostics in Beijing,
China, November 19-21, 2009. The Theme of the meeting is “New
Leadership